Shots:
- Ethris has entered into a collaboration agreement with Lonza to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates designed for mucosal delivery in pts with respiratory diseases
- As per the deal, Lonza will support Ethris’ vaccine candidates, which are based on Ethris’ stabilized non-immunogenic mRNA (SNIM RNA) & stabilized lipid nanoparticles (SNaP LNP) tech by providing spray-drying & particle engineering services at its Bend, US facility
- Collaboration will initially focus on developing a first-in-class intranasal mRNA vaccine candidate against influenza, with funding support from the Coalition for Epidemic Preparedness Innovations (CEPI)
Ref: Businesswire | Image: Ethris & Lonza
Related News:- Ethris Reports Topline Data from P-I trial of ETH47 for Uncontrollable Asthma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
